drugset / Trial / NCT02854579
Neural Progenitor Cell and Paracrine Factors to Treat Hypoxic Ischemic Encephalopathy
Unknown
120 enrolled
Navy General Hospital, Beijing
252 Military Hospital · collabBethune International Peace Hospital · collabDaping Hospital and the Research Institute of Surgery of the Third Military Medical University · collabHunan Children's Hospital · collabShangluo Central Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the efficacy and safety of allogenic neural progenitor cell and paracrine factors of human mesenchymal stem cells for patients with moderate/severe Hypoxic-Ischemic Encephalopathy
Timeline
- Start
- 2013-01
- Primary completion
- 2017-07
- Completion
- 2017-12
Publications
- Background Luan Z, Liu W, Qu S, Du K, He S, Wang Z, Yang Y, Wang C, Gong X. Effects of neural progenitor cell transplantation in children with severe cerebral palsy. Cell Transplant. 2012;21 Suppl 1:S91-8. doi: 10.3727/096368912X633806.
- Bruschettini M, Romantsik O, Moreira A, Ley D, Thebaud B. Stem cell-based interventions for the prevention of morbidity and mortality following hypoxic-ischaemic encephalopathy in newborn infants. Cochrane Database Syst Rev. 2020 Aug 19;8(8):CD013202. doi: 10.1002/14651858.CD013202.pub2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paracrine factors | Other / unclassified | 0.5 ml | Intrathecal |
| Subject | neural progenitor cell | Cell therapy | 4e+06 cells | Intrathecal |